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Jeffrey Hon-Sing Fung1, Ronnie Tung-Ping Poon1, Sheung Tat Fan1, Chung Mau Lo1 and Kwan Man1*Abstract
Background: Development of novel adjuvant therapy to eradicate tumor angiogenesis and metastasis is a pressing
need for patients with advanced hepatocellular carcinoma (HCC). We aimed to investigate the clinical relevance
and therapeutic potential of angiopoietin-like 4 (ANGPTL4) in HCC.
Methods: ANGPTL4 mRNA levels in tumor and non-tumor liver tissues of HCC patients were analyzed to investigate
its clinical relevance. The mechanisms of deregulation of ANGPTL4 in HCC were studied by copy number variation
(CNV) and CpG methylation analyses. The orthotopic liver tumor nude mice model was applied using a human
metastatic cell line. ANGPTL4-overexpressing adenovirus (Ad-ANGPTL4) was injected via portal vein to investigate its
anti-tumorigenic and anti-metastatic potentials.
Results: HCC tissues expressed significantly lower levels of ANGPTL4 mRNA than non-tumor tissues. The copy
number of ANGPTL4 gene in tumor tissues was significantly lower than in non-tumor tissues of HCC patients. Higher
frequency of methylation of CpG sites of ANGPTL4 promoter was detected in tumor tissues compared to non-tumor
tissues. Downregulation of ANGPTL4 mRNA in HCC was significantly associated with advanced tumor stage,
presence of venous infiltration, poor differentiation, higher AFP level, appearance of tumor recurrence, and poor
postoperative overall and disease-free survivals of HCC patients. Treatment with Ad-ANGPTL4 significantly inhibited
the in vivo tumor growth, invasiveness and metastasis by promoting tumoral apoptosis, inhibiting tumoral
angiogenesis and motility, and suppressing tumor-favorable microenvironment. Moreover, administration of
recombinant ANGPTL4 protein suppressed the motility of HCC cells and altered the secretion profile of cytokines
from macrophages.
Conclusion: ANGPTL4 is a diagnostic and prognostic biomarker for HCC patients and a potential therapeutic agent
to suppress HCC growth, angiogenesis and metastasis.
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Hepatocellular carcinoma (HCC) is one of the most ma-
lignant tumors and the fourth leading cause of cancer-
related death worldwide [1]. Surgical operations including
liver resection and liver transplantation are effectively
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unless otherwise stated.but patients with advanced HCC cannot be beneficial
from it. In addition to clinical shortcoming of chemore-
sistance of HCC causing ineffective implementation of
systemic chemotherapy and targeted therapy, patients
with advanced HCC have been often suffering from poor
prognosis [2-5]. Therefore, searching for novel adjuvant
therapies targeting HCC progression and metastasis is a
pressing need.
Angiopoietin-like 4 (ANGPTL4) protein, a secreted
protein, is one of the members of angiopoietin (ANG)-
relating family which shares very high similarity to theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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highly hydrophobic signal peptide, an N-terminal coiled-
coil domain and a C-terminal fibrinogen-like domain [6].
ANGPTL4 is expressed highly in numerous organs in-
cluding adipose tissue, liver, heart and small intestine
[7-9]. Moreover, ANGPTL4 can be stimulated by inflam-
matory and hypoxic conditions [6,7,10]. ANGPTL4 exerts
multifunctional roles such as glucose and lipid meta-
bolisms, inflammation, differentiation, angiogenesis, and
tumorigenesis [6,7]. The roles of ANGPTL4 in human
cancers are controversial. Overexpression of ANGPTL4
can promote tumorigenesis, tumor invasion, angiogenesis,
anoikis resistance and metastasis [11-15]. On the other
hand, ANGPTL4 is an anti-metastatic protein on tumor
cells through inhibition of vascular permeability, motility
and invasiveness [16]. The clinical implications and
functional roles of ANGPTL4 in HCC so far are not well
defined. One study has demonstrated that high level of
serum ANGPTL4 protein in HCC patients is significantly
associated with liver cirrhosis, higher histological grade
and intrahepatic metastasis [17]. However, a recent study
demonstrated that the expression levels of ANGPTL4
protein in tumor tissues are significantly lower than in
non-tumor tissues of HCC patients [18]. Our previous
study has demonstrated that ANGPTL4 plays important
roles in regulating glucose and lipid metabolisms of the
liver in mice [19]. In this study, we aimed to investigate
the clinical relevance of ANGPTL4 in HCC patients and
its therapeutic implication and underlying mechanisms on
HCC growth, angiogenesis and metastasis.
Results
Underexpression of ANGPTL4 in HCC
Quantitative RT-PCR was employed to study the expression
levels of ANGPTL4 mRNA in paired tumor and non-tumor
liver tissues from 110 HCC patients and in liver tissues
from 26 healthy donors. The average expression level (log2
base) of ANGPTL4 mRNA among tumor, non-tumor and
healthy donor liver tissues were 5.98, 7.13 and 6.98 respec-
tively (Figure 1A). The tumor tissues expressed a 2.2-fold
lower level of ANGPTL4 mRNA than non-tumor tissues of
HCC patients in average, which was statistically significant
using unpaired and paired t-tests (2-tailed unpaired t-test,
p < 0.0001; 2-tailed paired t-test, p < 0.0001). There was no
significant difference of ANGPTL4 mRNA between non-
tumor tissues and healthy liver tissues. Comparing paired
tumor and non-tumor tissues of each HCC patients,
51.82% (57/110) of tumor tissues were found to have lower
expression of ANGPTL4 mRNA while 16.36% (18/110)
of tumor tissues expressed higher ANGPTL4 mRNA
(Figure 1B). The expression levels of ANGPTL4 mRNA in
the 6 HCC cell lines were lower than in MIHA cell line
(Figure 1C). These data suggested that the expression of
ANGPTL4 mRNA was commonly downregulated in HCC.To understand the possible mechanism of downre-
gulation of ANGPTL4 in HCC, copy number variation
(CNV) analysis and CpG methylation analysis by pyro-
sequencing were performed in 40 pairs of tumor and
non-tumor DNA samples from HCC patients. The rela-
tive ANGPTL4 CNV value in tumor tissues of HCC pa-
tients was determined to be significantly lower than in
non-tumor tissues (p = 0.025, unpaired two-tailed t-test,
Figure 1D). The result from pyrosequencing showed that
there were 5 to 20% of positive methylations detected
among the 5 CpG sites of the ANGPTL4 promoter in
tumor tissues while there was no positive methylation de-
tected in all non-tumor tissues (Figure 1E). These data
suggested that hypermethylation of the promoter region
of ANGPTL4 gene may be one of the mechanisms leading
to downregulation of ANGPTL4 expression in HCC.
Clinical relevance and prognostic values of ANGPTL4
in HCC
Statistical analyses were performed to investigate the cli-
nical relevance and prognostic potential of ANGPTL4
mRNA in HCC. Comparing the expression levels of
ANGPTL4 mRNA between paired primary and recurred
tumor tissues in 5 HCC patients, 4 recurred tumors (80%)
were found to have significantly lower levels of ANGPTL4
mRNA than their matched primary tumors (Figure 1F).
Statistical analyses showed that either higher degree of
downregulation ANGPTL4 mRNA or lower expression
level of ANGPTL4 mRNA in tumor tissues of HCC
patients were significantly associated with presence of
venous infiltration, poor differentiation, advanced patho-
logic tumor-node-metastasis (pTNM) stage and presence
of recurrence (Table 1). Moreover, correlation analysis by
Pearson coefficient test showed that the expression of
ANGPTL4 mRNA was negatively correlated with serum
alpha fetoprotein (AFP) level, and overall and disease-free
survivals (Table 2). The above result suggested that the
degree of downregulation was positively correlated with
advanced stage of HCC and poor survivals of HCC
patients. The expression level of ANGPTL4 mRNA in
non-tumor tissues of HCC patients was not significantly
associated with any clinical factors (Tables 1 and 2).
To obtain an optimal cutoff point for examining the
prognostic value of ANGPTL4 mRNA in HCC patients,
Receiver operating characteristic (ROC) curve was gene-
rated to analyze the sensitivity and 1-specificity using the
value of ΔΔΔCt(ANGPTL4patient) to predict the 1
st year
postoperative overall survival of HCC patients (Figure 2A).
The under area of ROC curve was determined as 0.677.
According to Youden index, the optimal cutoff value
of ΔΔΔCt(ANGPTL4patient) among HCC patients was
determined to be −1.585. Sixty-seven (60.90%) and 43
(39.09%) HCC patients were defined as ANGPTL4 mRNA
Non-downregulation group and Downregulation group.
Figure 1 Downregulation of ANGPTL4 gene in HCC. (A) Expression profile of ANGPTL4 mRNA among 26 healthy liver tissues and 110 HCC
patients. (B) Summary of expression difference of ANGPTL4 mRNA between paired tumor and non-tumor liver tissues among 110 HCC patients.
Lower, expression in tumor was 2-fold lower than in non-tumor; Similar, expression in tumor was neither 2-fold higher non 2-fold lower than in
non-tumor; Higher, expression in tumor was 2-fold higher than in non-tumor. (C) Relative expression level ratio of ANGPTL4 mRNA in HCC cell
lines to normal liver cell line. (D) Copy number variation (CNV) analysis of ANGPTL4 gene in healthy donors and HCC patients. The DNA samples
for CNV analysis were randomly selected from those used for mRNA analysis. (E) Methylation analysis of ANGPTL4 promoter in HCC patients by
pyrosequencing. (F) Relative expression ratio of ANGPTL4 mRNA between primary and recurred tumor tissues of HCC patients. *, P < 0.05;
**, P < 0.01.
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Table 1 Statistical analysis of ANGPTL4 mRNA with clinical factors of HCC patients using two-tailed T-test
ANGPTL4 mRNA in HCC patients
Tumor/non-tumor difference Tumor Non-tumor
Clinical factors Number (n) Mean (Log2) P Mean (Log2) p Mean (Log2) p
Sex
Male 88 −1.20 0.889 5.85 0.381 7.15 0.670
Female 22 −1.12 6.32 7.02
Venous infiltration
Absent 51 −0.67 0.023* 6.51 0.012* 7.18 0.692
Present 59 −1.63 5.45 7.08
Differentiationa
Moderately or well 87 −0.82 0.000*** 6.21 0.013* 7.17 0.639
Undifferentiated or poorly 18 −3.21 4.80 7.01
pTNM staginga
Early stage 34 −0.35 0.007** 6.67 0.025* 7.04 0.646
Advanced stage 75 −1.56 5.66 7.16
Cirrhosisa
No cirrhosis 39 −0.97 0.479 5.98 0.981 6.98 0.382
Cirrhosis 69 −1.29 5.97 7.20
Recurrence
No recurrence 49 −0.69 0.035* 6.58 0.006** 7.20 0.577
Recurrence 61 −1.58 5.43 7.07
Hepatitis B surface antigen
Negative 16 −0.99 0.700 5.53 0.429 6.61 0.080
Positive 94 −1.22 6.01 7.22
aTotal number less than 110 due to missing data; *, p<0.05; **, p<0.01; ***, p<0.001.
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Downregulation group was significantly associated with
poor overall survival rate (p = 0.003, Figure 2B) and
poor disease-free survival rate (p = 0.015, Figure 2C) of
the patients after hepatectomy compared to patients in
Non-downregulation group. The mean periods of post-
operative overall and disease-free survivals for Down-
regulation group were 61.7 and 41.2 months, while for
Non-downregulation group were 93.0 and 66.7 months.
Univariable Cox regression hazard analysis showed thatTable 2 Correlation analysis of ANGPTL4 mRNA with clinical f
Tumor/non-tumor d
Clinical factors Number (n) Pearson
correlation (R)
Age (Year) 110 −0.039
AFP level (mg/ml) 110 −0.276
Tumor sizea (cm) 95 0.017
Overall survival (Month) 110 0.289
Disease-free survival (Month)b 109 0.241
aTotal number less than 110 due to missing data. bTotal number less than 110 dueANGPTL4 mRNA was a significant prognostic biomarker
for predicting postoperative overall and disease-free
survivals of HCC patients (Table 3). The above results
suggested that ANGPTL4 mRNA may be a prognostic bio-
marker for HCC patients after hepatectomy.
ANGPTL4 suppressed HCC tumorigenesis and metastasis
The therapeutic potential of ANGPTL4 treatment was
examined in an orthotopic xenograft liver tumor model in
mice. The result showed that injection of Ad-ANGPTL4actors of HCC patients
ANGPTL4 mRNA in HCC patients
ifference Tumor Non-tumor
P Pearson
correlation (R)
p Pearson
correlation (R)
p
0.682 −0.084 0.382 −0.038 0.693
0.004** −0.263 0.005** 0.051 0.593
0.871 0.077 0.456 0.186 0.071
0.002** 0.230 0.016* −0.123 0.201
0.012* 0.266 0.005** −0.032 0.740
to one patients was out of selection; *, p<0.05; **, p<0.01.
Figure 2 Survival analyses of ANGPTL4 mRNA in HCC patients.
(A) Receiver operating characteristic (ROC) curve analysis of ANGPTL4
mRNA on predicting 1-year overall survival of HCC patients after liver
resection. (B) Kaplan-Meier analysis of ANGPTL4 mRNA on predicting
overall survival of HCC patients after hepatectomy. (C) Kaplan-Meier
analysis of ANGPTL4 mRNA on predicting disease-free survival of
HCC patients after hepatectomy. *, P < 0.05; **, P < 0.01.
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cantly hindered tumor formation from 3 weeks to 6 weeks
(Figure 3A). The average tumor volume at week 6 was
reduced by 11.6 folds after Ad-ANGPTL4 treatment com-
pared to the control group (Figure 3B). Moreover, sig-
nificant inhibitions of distant metastases including lung,
abdominal and multi-organ metastases at week 6 were
detected in Ad-ANGPTL4 treatment group compared to
the control group (Figure 3C). Histological examination re-
vealed that liver tumors in the control group exhibited pro-
gressive morphologies including disrupted encapsulation
and infiltrated tumor thrombus, while in Ad-ANGPTL4
treatment group, most of the tumors were surround
by intact capsules and without venous-infiltrated tumor
thrombus (Figure 4A). Moreover, the non-tumor liver
tissues remained normal after Ad-ANGPTL4 treatment
(Figure 4A). Histological examination of consecutive lung
tissue sections also confirmed a significant reduction of
lung metastasis at week 5 after Ad-ANGPTL4 treatment
compared to the control group (Figure 4A). Consistently,
transmission electron microscopy analysis revealed that
Ad-ANGPTL4 treatment disrupted the integrity of the
tumor endothelial cells and suppressed the invasiveness of
the tumor compared to the control group (Figure 4B).
These date suggested that ANGPTL4 may be a potential
therapeutic agent to suppress HCC growth and metastasis.
ANGPTL4 promoted tumor apoptosis and inhibits tumor
angiogenesis
To understand the possible mechanisms of ANGPTL4
on suppressing HCC growth, its effects on apoptosis and
angiogenesis of HCC were studied. The result showed
that Ad-ANGPTL4 treatment significantly increased the
number of intratumoral apoptotic cells by approximately
3 folds compared to the control group (Figure 5A).
Moreover, administration of recombinant ANGPTL4
(rANGPTL4) protein could increase the activation of
caspase 7 and 9, and downregulated the expression of
anti-apoptotic protein Bcl2 (Figure 5D). These data sug-
gested that ANGPTL4 could promote apoptosis of HCC
cells. In order to study the effect of ANGPTL4 on angio-
genesis of HCC, the intratumoral microvessel density
(MVD) which indicates the formation of new vessels was
determined by immunohistochemical staining of CD34
antibody. The result showed that Ad-ANGPTL4 treat-
ment significantly decrease the MVD by 4 folds in tumor
Table 3 Cox proportional hazard regression analysis of ANGPTL4 mRNA and clinicopathological parameters in relation
to the overall and disease-free survivals of HCC patients after hepatectomy
Univariable analysis Multivariable analysis
HR (95% CI) P HR (95% CI) P
1. Overall survival
ANGPTL4 mRNA
Downregulation vs Non-downregulation 2.39(1.33-4.27) 0.003** 1.48(0.81-2.72) 0.204
pTNM staging
Advanced vs early 5.37(2.25-12.81) 0.000*** 2.26(0.71-7.18) 0.168
Venous infiltration
Presence vs absence 4.41(2.25-8.67) 0.000*** 2.11(0.88-5.09) 0.096
AFP level
>20 ng/ml vs ≤20 ng/ml 3.10(1.60-5.99) 0.001** 2.12(1.07-4.21) 0.031*
2. Disease-free survival
ANGPTL4 mRNA
Downregulation vs Non-downregulation 1.83(1.12-2.99) 0.017* 1.40(0.84-2.32) 0.201
pTNM staging
Advanced vs early 2.87(1.57-5.24) 0.001** 1.33(0.53-3.35) 0.544
Venous infiltration
Presence vs absence 3.14(1.84-5.37) 0.000*** 2.36(1.06-5.26) 0.036*
Abbreviations: HR hazard ratio, CI confidence interval; *, p<0.05; **, p<0.01; ***, p<0.001.
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ANGPTL4 can suppress angiogenesis of HCC. Further-
more, Western blot analysis showed that Ad-ANGPTL4
treatment could inhibit the expression of VEGF protein
and phosphorylation of Raf-MEK-Erk signaling pathway
of HCC (Figure 5C). Administration of rANGPTL4
protein on HCC cells also inhibit the expression of VEGF
and activation of Raf-MEK-Erk pathways (Figure 5D).
These data suggested an anti-angiogenic effect of
ANGPTL4 on HCC.
ANGPTL4 suppressed the motility of HCC cells
In order to understand the mechanism of ANGPTL4 on
suppressing HCC metastasis, its effect on HCC motility
was investigated. ROCK1 is an important player in regula-
ting the motility and migration of cancer cells [20]. Western
blot analysis showed that treatment of Ad-ANGPTL4 sup-
pressed the expression of ROCK1 protein in tumor tissues
compared to the control group (Figure 6A). In vitro experi-
ment showed that administration of rANGPTL4 protein on
HCC cell lines suppressed the their formation of poly-
merized stress fibers which indicated by F-actin staining
(Figure 6B). Under scanning electronic microscopy, the
formation of hair-like fiber structure of Hep3B and
MHCC97L cells was suppressed after administration of
rANGPTL4 protein (Figure 6C). Western blot analysis
showed that rANGPTL4 protein decreased the expressionof ROCK1 protein in MHCC97L cells (Figure 6D). These
data suggested that ANGPTL4 could suppress the motility
of HCC cells thereby reduce their metastatic ability.
ANGPTL4 influenced tumor-microenvironment
The ability to manipulate the microenvironment is one of
the hallmarks of cancer to promote tumor progression, in-
vasion and metastasis [21]. The effect of ANGPTL4 treat-
ment on tumor-microenvironment was therefore studied
from different aspects. Compared to the control group,
the number of activated hepatic stellate cells (HSCs),
revealed by immunohistochemical staining of α-smooth
muscle actin (α-SMA) protein, was significantly suppressed
after Ad-ANGPTL4 treatment (Figure 7A). The number of
infiltrated tumor-associated macrophages (TAMs) stained
by anti-CD68 antibody in xenograft liver tumor was signifi-
cantly reduced after Ad-ANGPTL4 treatment (Figure 7B).
Western blot analysis showed that MMP-12 protein was
down-regulated in Ad-ANGPTL4 treatment group com-
pared to the control group (Figure 7C). Administration of
rANGPTL4 protein to mouse macrophage cell line altered
the profile of secreted cytokines including up-regulations
of CD30L, CD30T, CD40, CRG2, CTACK, CXCL16,
eotaxin and L-selectin, and down-regulations of SDF-1α,
TARC, TCA-3, TECK, TIMP-1, TNFα and STNFR1
(Figure 7D). These data suggested that ANGPTL4 can des-
troy the tumor-favorable microenvironment in HCC.
Figure 3 Therapeutic implication of ANGPTL4 in suppression in vivo tumor growth and metastasis of HCC. (A) In vivo imaging of
xenograft liver tumor in nude mice between control and ANGPTL4 treatment groups at week 0, 2, 3, 4, 5 and 6. (B) Liver tumor formation at
week 6 between control and ANGPTL4 treatment groups (C) In vivo imaging of metastases on lung at week 6 after covering the luciferase signal
from the primary liver tumor. *, P < 0.05.
Ng et al. Molecular Cancer 2014, 13:196 Page 7 of 17
http://www.molecular-cancer.com/content/13/1/196
Figure 4 ANGPTL4 suppressed in vivo invasiveness and metastasis of HCC. (A) Hematoxylin-eosin staining of liver and lung tissues between
control and ANGPTL4 treatment group at week 6. The arrow heads in Ad-Luc group indicate the presence of tumor thrombus in the control group,
while the arrowheads in the treatment group indicate the intact encapsulation surrounding the tumor. T, tumor; NT, non-tumor. (B) Ultrastructure of
liver tumor tissues by transmission electron microscopy. In the control group, the liver tumor was observed to have (1) intact endothelial cells indicated
by arrows, (2) infiltrated tumor cells into vessels and (3) invasive phenotype. In Ad-ANGPTL4 treatment group, the liver tumor was observed to have
(4 & 5) disrupted endothelial cells indicated by the arrows and (6) intact tumor capsule.
Ng et al. Molecular Cancer 2014, 13:196 Page 8 of 17
http://www.molecular-cancer.com/content/13/1/196
Figure 5 (See legend on next page.)
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Figure 5 ANGPTL4 promoted apoptosis and suppressed angiogenesis of HCC. (A) TUNEL assay on liver tumor tissues. (B) Determination
of microvessel density (MVD) of liver tumor tissues by immunohistochemical staining using anti-CD34 antibody. (C) Western blot analysis of VEGF,
phosphor-Raf, Phospho-MEK, Phospho-Erk, ANGPTL4 and beta-actin proteins in liver tumor tissues in Ad-ANGPTL4 and Ad-Luc groups. The average
protein expression between Ad-ANGPTL4 and Ad-Luc group was quantified and summarized in the lower panel figures. (D) Western blot analysis of
proteins in MHCC97L cells after treating with rNGPTL4 protein. *, P < 0.05.
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There have been several studies suggesting that ANGPTL4
is deregulated in cancers, whether it is elevated or sup-
pressed in tumor is dependent on the types and the con-
texts of cancers [6]. The expression profile of ANGPTL4
in HCC patients is diverse so far. One study has demon-
strated that serum ANGPTL4 protein in HCC patients is
higher than in chronic hepatitis B patients and normal
controls [17]. However the study did not indicate whether
the expression of ANGPTL4 in HCC tissues is deregulated
or not [17]. Zhu has demonstrated that ANGPTL4 protein
is upregulated in tumor tissues of HCC patients compared
to normal liver tissue, but only 2 HCC samples were ex-
amined on tissue arrays [13]. Another study has found that
ANGPTL4 protein in carcinoma tissues is significantly
lower than in adjacent tissues of HCC patients [18]. In our
study, the overall expression level of ANGPTL4 mRNA in
tumor tissues of HCC patients was lower than non-tumor
tissues and healthy liver tissues. Moreover, the number of
patients having lower ANGPTL4 mRNA expression in
HCC was greater than the number of having higher
ANGPTL4 mRNA expression in HCC. Furthermore, the
relative expression levels of ANGPTL4 mRNA in 6 HCC
cell lines were lower than the normal liver cell line.
Therefore, our above evidences suggested that ANGPTL4
mRNA is underexpressed in HCC. ANGPTL4 gene locates
in chromosome 19p13.3. Several lines of evidences have
proved that chromosome 19p is one of the most frequently
deleted chromosomal regions in HCC [22-24]. Moreover,
a finding in gastric cancer has suggested that methylation
is a mechanism of silencing ANGPTL4 gene leading to
tumor development [25]. Methylation of ANGPTL4 gene
has also been found in primary breast cancer [26]. Our
CNV and methylation analyses demonstrated that lower
copy number of ANGPTL4 gene and presence of methyla-
tion in the promoter of ANGPTL4 gene might contribute
to decreased expression of ANGPTL4 gene in HCC.
Downregulation of ANGPTL4 mRNA in HCC was
found to be significantly associated with poor prognosis
after curative surgery. The clinicopathological parame-
ters of the patients with higher degree of downregulation
of ANGPTL4 were significantly associated with higher
malignancy of HCC including advanced HCC stage,
presence of venous infiltration, poor differentiation,
higher AFP level and appearance of postoperative tumor
recurrence. One of the functions of ANGPTL4 is invol-
ving in regulating cell differentiation [7]. Our resultdemonstrated that patients with undifferentiated or
poorly differentiated HCC had significantly lower levels
of ANGPTL4 mRNA in tumor tissues (Table 1), sugges-
ting that deregulation of ANGPTL4 mRNA may indicate
the status of tumor differentiation. In addition, most of
the recurred HCC tumors expressed lower levels of
ANGPTL4 mRNA than the primary tumors. These above
results indicated that the expression level of ANGPTL4
mRNA in HCC is reversely correlated with tumor malig-
nancy. Most importantly, patients with downregulation
of ANGPTL4 mRNA in HCC were significantly asso-
ciated with poor postoperative overall and disease-free
survivals. Therefore, our data suggested that ANGPTL4
mRNA may be a potential diagnostic and prognostic
biomarker for HCC patients.
ANGPTL4 exhibits both pro-tumorigenic and anti-
tumorigenic properties depending on the tissue contexts
and the status of posttranslational modifications [6]. Over-
expression of ANGPTL4 can inhibit the motility, invasive-
ness and metastasis of Lewis lung carcinoma and mouse
skin cancer cells [16]. However, many studies have sug-
gested that ANGPTL4 can promote tumor growth, angio-
genesis, invasion and metastasis [11-15]. A study in HCC
has showed that ANGPTL4 promotes tumor migration
and metastases [17]. Our study demonstrated that treat-
ment with Ad-ANGPTL4 significantly suppressed not
only the in vivo growth, angiogenesis and invasiveness,
but also the extrahepatic multiorgan metastases of HCC.
In addition, treatment with Ad-ANGPTL4 did not cause
potential deleterious side effects on the liver tissues. These
results suggested that ANGPTL4 may be a potential
therapeutic agent for treatment of HCC.
Our study demonstrated several mechanisms of
ANGPTL4 in suppressing tumor progression, invasion
and metastasis of HCC. First, overexpression of ANGPTL4
suppressed tumor growth through enhancing apoptosis of
tumor cells, indicating that suppression of ANGPTL4 in
HCC may be a way to escape from apoptosis. Second,
overexpression of ANGPTL4 could suppress the inva-
siveness of HCC cells by restraining its motility through
suppression the expression of ROCK1 and formation of
polymerized stress fibers. ANGPTL4 is an important regu-
lator involved in vascular permeability and angiogenesis
[6,7]. In this study, Ad-ANGPTL4 treatment significantly
suppressed the formation of new vessels in the tumor
through repressing the expression of angiogenic factor
VEGF and suppressing the activation of Raf-MEK-Erk
Figure 6 (See legend on next page.)
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Figure 6 ANGPTL4 suppressed the motility of HCC. (A) Western blot analysis of ROCK1 protein in tumor xenograft between Ad-ANGPTL4 treatment
group and the Ad-Luc control group. Up-regulation of ANGPTL4 protein by Ad-ANGPTL4 treatment was validated in Figure 5C. (B) The effect of
rANGPTL4 protein on formation of polymerized stress fibers in HCC cells, indicated by immunostaining of F-actin using rhodamine-phalloidin probe.
Red color, F-actin signal; Blue color, nucleic staining by DAPI. The level of ANGPTL4 protein in cells and medium was determined by Western blot
analysis (C) Scanning electron microscopy of the morphology of HCC cells after administration of rANGPTL4 protein. Red arrows indicate the formation
of extracellular “hair-like” stress fibers. (D) Western blot analysis of ROCK1 protein in MHCC97L cells after administration of rANGPTL4 protein.
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ANGPTL4 on HCC. Angiogenesis which is one of the
hallmarks of cancer for obtaining oxygen and nutrients
and eliminating wastes is critical for tumorigenesis and
metastasis processes [21]. Targeted therapy on inhibiting
angiogenesis of HCC has increasingly become one of the
important therapeutic strategies in treating patients with
advanced HCC [27,28]. Modulating tumor microenviron-
ment to promote tumor progression, invasion and metas-
tasis is one of the hallmarks of cancer [21]. Myofibroblast
which is one of the cancer-associated fibroblasts can be re-
cruited by tumor cells to promote tumor progression and
metastasis [21]. Activation of HSCs has been demon-
strated to promote HCC progression by generating proin-
flammatory and proangiogenic microenvironment [29]. In
this study, the expression of intratumoral αSMA was sup-
pressed by Ad-ANGPTL4 treatment. Because αSMA is
marker for myofibroblast and activated HSCs, suppression
of intratumoral αSMA by Ad-ANGPTL4 indicated its po-
tential to inhibit infiltrated myoblasts and the activation of
HSCs. HCC is an inflammation-associated cancer in which
infiltrated tumor-associated macrophages (TAMs) play
critical roles in tumor microenvironment to promote
tumorigenesis and progression through secreting cytokines,
chemokines and growth factors [30]. MMP-12 which is a
proinflammatory factor mainly produced by macrophages
is overexpressed in HCC [31]. In our study, the number of
infiltrated TAMs was reduced by Ad-ANGPTL4 treatment
along with the suppression of MMP-12 expression. More-
over, administration of rANGPTL4 protein could alter the
secretions of cytokines from macrophages, indicating its
ability to influence the activity of macrophages. Therefore,
these results suggested that ANGPTL4 may suppress
HCC progression and metastasis through deterioration of
tumor-favorable microenvironment. The direct effects and
mechanisms of ANGPTL4 on regulating tumor micro-
environment of HCC are needed further investigation.
In summary, our data demonstrated that ANGPTL4
mRNA was commonly underexpressed in HCC. Down-
regulation of ANGPTL4 mRNA in HCC was significantly
associated with advanced HCC stage, presence of venous
infiltration, higher AFP level, poor differentiation, ap-
pearance of tumor recurrence, and poor postoperative
overall and disease-free survivals of HCC patients. Most
importantly, ANGPTL4 treatment could suppress HCC
progression and metastasis through promotion of tumorapoptosis, inhibition of tumor motility and angiogenesis,
and disruption of tumor-favorable microenvironment.
Taken together, our data suggested that ANGPTL4 may
be a potential prognostic biomarker and therapeutic
agent for patients with advanced HCC.
Materials and methods
Patients
Paired tumor and non-tumor liver tissues were recruited
from 110 HCC patients undergone liver resection. Paired
primary and recurred tumor and non-tumor liver tissues
were recruited from 5 HCC patients. Twenty-six normal
liver tissues were recruited. The HCC patients were re-
ceived operation in the Department of Surgery, Queen
Marry Hospital, the University of Hong Kong, from
December 1999 and October 2007. The study was
approved by the Ethics Committee of the University of
Hong Kong.
Cell lines
A human normal liver cell line named MIHA, 4 human
HCC cell lines including HepG2, Huh7, PLC and Hep3B,
and a mouse macrophage cell line named Raw264.7 were
purchased from American Type Culture Collection. Two
human metastatic HCC cell lines, MHCC97L and
MHCC97H, were the kind gifts from Liver Cancer Insti-
tute, Fudan University, Shanghai, China. The cell lines
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) with high glucose (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum (Invitrogen),
100 mg/ml penicillin G and 50 μg/ml streptomycin
(Invitrogen) at 37°C in a humidified atmosphere contain-
ing 5% CO2. MHCC97L cell line stably labeled with the
luciferase gene, named MHCC97L-Luc [32], was used for
in vivo study.
Orthotopic xenograft nude mice liver tumor model
Male athymic nude mice (BALB/c-nu/nu, 4 – 6 weeks
old) were used. Approximately 6 × 105 MHCC97L-Luc
cells in 0.2 ml of culture medium were injected subcuta-
neously in the nude mouse. When the subcutaneous
tumor nodule reached 0.8 – 1 cm in diameter, it was re-
moved and cut into cubes about 1 – 2 mm3 in size, which
were then implanted into the left liver lobes of another
group of nude mice, using the method described pre-
viously [32,33]. Then, full-length ANGPTL4-overexpressing
Figure 7 ANGPTL4 modulated tumor microenvironment. (A) Immunohistochemical staining of α-SMA protein on liver tumor tissues.
(B) Determination of tumor associated macrophage (TAM) in liver tumor tissues by immunohistochemical staining of CD68 protein. (C) Western
blotting of MMP-12 protein in liver tumor tissues between Ad-ANGPTL4 treatment group and Ad-Luc control group. Up-regulation of ANGPTL4
protein by Ad-ANGPTL4 treatment was validated in Figure 5C. (D) Cytokine array analysis of the media of Raw264.7 cells. *, P < 0.05.
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overexpressing adenovirus (Ad-Luc control group) was
injected into the portal vein of each mouse (108 IU/
mouse). The size of the in vivo liver tumor and lungmetastasis were monitored by Xenogen IVIS® imaging sys-
tem every week. The mice were sacrificed at 6-weeks after
implantation. Six mice were performed for each group.
Animal study was approved by Animal (Control of
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of Health, Hong Kong Special Administrative Region
(Ref.: (11–371) in DH/HA&P/8/2/3 Pt. 29).Real-time quantitative RT-PCR (qRT-PCR)
Total RNA from cells and liver tissues were purified by
TriZol Regent (Invitrogen). The quality of RNAs was ana-
lyzed by Nanodrop 1000 analyzer (Thermo Scientific) and
RNA gel electrophoresis. Method of qRT-PCR analysis
was described as in previous study [31]. The expression
level of 18S ribosomal RNA and beta-actin was used as
the internal control for clinical samples [31,34] and cells,
respectively. Primers used in this study included human
ANGPTL4 gene, sense: 5′-TGACCTCAGATGGAGGC
TGGACA-3′, antisense: 5′-CAGCCAGAACTCGCCG
TGGG-3′; 18S ribosomal RNA, sense 5′-CTCTTAGCT
GAGTGTCCCGC-3′, antisense 5′-CTGATCGTCTTC
GAACCTCC-3′; human beta-actin gene, sense: 5′-CTC
TTCCAGCCTTCCTTCCT-3′, antisense: 5′-AGCACTG
TGTTGGCGTACAG-3′. The relative expression level of
ANGPTL4 mRNA for each clinical sample was calculated
as: ΔΔCt(ANGPTL4sample) =ΔCt(ANGPTL4calibrator) – ΔCt
(ANGPTL4sample), where ΔCt(ANGPTL4calibrator) = Ct(AN
GPTL4calibrator) – Ct(18Scalibrator); ΔCt(ANGPTL4sample) =
Ct(ANGPTL4sample) – Ct(18Ssample). The calibrator was
defined as the sample whose threshold cycle (Ct) value of
ANGPTL4 mRNA was the highest (i.e. sample with the
lowest expression level of ANGPTL4 mRNA) among all
samples. The relative expression level of ANGPTL4
mRNA was presented as relative fold difference in log2
base [31,35]. The difference of ANGPTL4 mRNA between
tumor and non-tumor tissues of each HCC patient was
determined as: ΔΔΔCt(ANGPTL4patient) =ΔΔCt(ANGP
TL4tumor) – ΔΔCt(ANGPTL4non-tumor). The value of
ΔΔΔCt was equal to 2-ΔΔΔC fold change. PCR analysis for
each sample was performed in triplicate.Copy number variation (CNV) analysis
Ten DNA samples from healthy donors and forty-pairs of
DNA samples from tumor and non-tumor tissues of HCC
patients were extracted using Qiagen DNA extraction kit
(Qiagen). 10 μg of each DNA sample was used for CNV
analysis by using ANGPTL4 specific TaqMan copy num-
ber assay (FAM-labeled, Life Technologies). The RNase P
gene (VIC-labeled, Life Technologies) was used as control.
The PCR analysis was performed by using TaqMan Uni-
versal Master Mix II (Life Technologies) and analyzed in
the ViiA7 Real Time PCR system (Life Technologies). The
relative ANGPTL4 CNV for each sample was determined
as ΔΔCt(ANGPTL4sample) =ΔCt(ANGPTL4calibrator) – ΔCt
(ANGPTL4sample), where ΔCt(ANGPTL4calibrator) = Ct
(ANGPTL4calibrator) – Ct(RNasePcalibrator); ΔCt(ANGP
TL4sample) = Ct(ANGPTL4sample) – Ct(RNasePsample). Thecalibrator is the sample with the lowest ANGPTL CNV.
PCR analysis for each samples was performed in triplicate.
CpG methylation analysis of ANGPTL4 promoter by
pyrosequencing
Forty-pairs of DNA samples were extracted from tumor
and non-tumor tissues of HCC patients using Qiagen
DNA extraction kit (Qiagen). Each DNA was performed
bisulfite conversion by EZ DNA Methylation-Direction
KIT (Zymo Research). A predesigned ANGPTL4 Pyro-
Mark CpG Assay (Hs_ANGPTL4_01_PM, Qiagen) was
purchased for quantification of CpG methylation of
ANGPTL4 promoter. There were 5 CpG sites in the
construct. PCR amplification was performed by using
PyroMark® PCR Kit (Qiagen). Pyrosequencing analysis
was performed by Genome Research Center, The Uni-
versity of Hong Kong. The sequencing data was analyzed
by Pyro Q-CpG Software (Biotage). The percentage of
methylation >10% was defined as positive methylation.
Western blot
Method of Western blot analysis was described in previ-
ous study [36]. The amount of 20 μg of total protein from
each sample was used for loading. Antibodies including
vascular endothelial growth factor (VEGF), ROCK1,
Matrix metalloproteinase-12 (MMP-12) and beta-actin
antibody were purchased from Santa Cruz Biotechnology
(CA). phospho-Raf(Ser259), Phospho-MEK1/2, phosopho-
Erk1/2, Bcl-2, cleaved-caspase 7, and cleaved-caspase 9
antibodies were purchased from Cell Signaling Technol-
ogy. The intensity of Western blot analysis was quantified
by Quantity One software (Bio-Rad).
Morphological study by light and transmission electron
microscopy
Liver tumor tissues including non-tumor margin were
taken at different time points after tumor implantation
for light microscopy with hematoxylin-eosin staining.
The specimens were immediately cut into 1-mm cubes
and fixed in 2.5% glutaraldehyde in sodium carcodylate
hydrochloride buffer overnight at 4°C for electron mi-
croscopy section. The sections were then examined
under a transmission electron microscope, Philips EM
208 (Koninklijke Philips Electronics N.V., Eindhoven,
Netherlands).
Ultrastructural examination by scanning electron
microscopy
Cells treated with or without recombinant ANGPTL4
(rANGPTL4) protein grown on sterile round glass cover
slips were fixed with 2.5% glutaraldehyde in 0.1 M sodium
cacodylate-HCl buffer, pH 7.4, quenched with 0.1 M
sucrose/cacodylate solution, and washed in cacolydate
buffer. The samples were then post-fixed with 1% OsO4
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were dehydrated through a graded series of ethanol washes,
followed by critical point drying using BAL-TEC CPD 030
Critical Point Dryer (BAL-TEC AG, Liechtenstein). The
samples were then sputter-coated with a layer of gold
using BAL-TEC SCD 005 Sputter Coater (BAL-TEC AG),
and visualized using Leica Cambridge Stereoscan 440
SEM (Leica, Cambridge, UK) at an accelerating voltage of
12 kV.
Immunohistochemistry
Paraffin sections were de-waxed in xylene, rinsed in grade
alcohol, and rehydrated in water. Then they were placed
in citric buffer (pH 6.0) and treated in a microwave oven
with high power for 3 minutes and subsequent low power
for 10 minutes. Afterwards, the sections underwent block-
ing with 3% peroxidase for 20 minutes and 10% goat
serum for 30 minutes. Subsequently, primary antibodies
with proper dilution were applied on the sections, which
were then incubated at 4°C overnight. Following that,
secondary antibodies from Dako EnVision™ System
(DakoCytomation, Glostrup, Denmark) were applied, and
the sections were incubated for 30 minutes at room
temperature. Signals were developed with DAB substrate
solution (DakoCytomation). The sections were finally
counter-stained by hematoxylin solution. Primary anti-
bodies used in this study included VEGF (Santa Cruz
Biotechnology), alpha smooth muscle actin (α-SMA,
DakoCytomation), CD34 (Santa Cruz Biotechnology), and
CD68 (BD Biosciences, San Jose, CA, USA).
Determination of microvessel density (MVD)
MVD of liver tumor tissue sections was evaluated by im-
munohistochemical staining with CD34 antibody [37].
Any CD34-positive stained endothelial cell or endothelial
cell cluster that was clearly separated from adjacent
microvessels, tumor cells and connective elements was
counted as one microvessel. The mean microvessel count
of the five most vascular areas was taken as the MVD,
which was expressed as the absolute number of microves-
sels per 1.485 mm2 (×200 field).
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
Paraffin sections of liver tumor tissues from the treat-
ment group and the control group were detected for
apoptotic cells by In Situ Cell Death Detection Kit
(Roche) according to the manufacturer’s protocol.
Cytokine array assay
RAW264.7 cells were seeded onto a 6-well plate and incu-
bated at 37°C with 5% CO2 for 24 hours. Then the cells
were treated with DMEM medium containing 2.5 μg/ml
of recombinant mouse ANGPTL4 protein (Obtained fromProf. Aimin Xu, Department of Medicine, the University
of Hong Kong) for 24 hours. Cytokine profiling of the
medium was analyzed with RayBio® Mouse Cytokine Anti-
body Array (Cat# AAM-CYT-3, RayBiotech Inc.) accor-
ding to manufacturer’s instruction.
Immunofluorescent staining
Cells were fixed with 4% paraformaldehyde in PBS for
15 min at room temperature, and permeabilized with 0.5%
Triton X-100 in PBS for 15 min. The cells were blocked
with 1% bovine serum albumin in PBS for 30 minutes and
then incubated with rhodamine phalloidin probe (Invitro-
gen) for 1 h at room temperature. After 3 washes in PBS,
the cells were stained with DAPI at room temperature for
10 minutes. The cells were washed 3 times with PBS and
mounted with FluorSave Reagent (Calbiochem). The slides
were analyzed by an image analysis system (Eclipse E600,
Nikon).
Statistical analysis
For clinical samples, the associations of ANGPTL4 mRNA
with clinicopathological parameters were analyzed by two-
tailed t-test (Sex, Venous infiltration, differentiation,
pTNM staging, cirrhosis, recurrence and hepatitis B sur-
face antigen) or correlation analysis (Age, serum AFP level,
tumor size, duration overall survival and duration of
disease-free survival). Receiver Operating Characteristic
(ROC) curve was generated to analyze the sensitivity and
1-specificity of ΔΔΔCt(ANGPTL4patient) value to predict
1st year overall survival of HCC patients after hepatectomy.
Youden index was used to determine Non-downregulation
group and Downregulation group of HCC patients. The
prognostic value of ANGPTL4 mRNA in predicting overall
and disease-free survivals of HCC patients after hepatic re-
section was calculated by Kaplan-Meier analysis with the
log-rank test. For disease-free survival analysis, HCC
patients under the category of hospital mortality were ex-
cluded. Cox proportional hazard regression model was per-
formed with univariable and multivariable analyses to test
factors that were significantly associated with the postoper-
ative overall survival and disease-free survival of the HCC
patients. For animal study, continuous variables were
expressed as median with range. Mann–Whitney U test
was used for statistical comparison. Chi-square (χ2) test
was used to compare incidence of lung metastasis in the
nude mice orthotopic liver tumor model. Calculations were
made with SPSS computer software (SPSS Inc., Chicago,
IL, USA). P value < 0.05 was considered to be statistically
significant.
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